Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.185 AUD | +2.78% | +8.82% | +2.78% |
Apr. 23 | Microba's Revenue Climbs 297% in Fiscal Q3 | MT |
Apr. 10 | Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% | MT |
Sales 2024 * | 11.81M 7.75M | Sales 2025 * | 17.97M 11.79M | Capitalization | 80.61M 52.91M |
---|---|---|---|---|---|
Net income 2024 * | -17M -11.16M | Net income 2025 * | -16M -10.5M | EV / Sales 2024 * | 5.09 x |
Net cash position 2024 * | 20.45M 13.42M | Net cash position 2025 * | 17.07M 11.2M | EV / Sales 2025 * | 3.54 x |
P/E ratio 2024 * |
-4.62
x | P/E ratio 2025 * |
-4.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.75% |
1 day | +2.78% | ||
1 week | +8.82% | ||
Current month | -11.90% | ||
1 month | -11.90% | ||
3 months | +2.78% | ||
6 months | -19.57% | ||
Current year | +2.78% |
Managers | Title | Age | Since |
---|---|---|---|
Luke Reid
CEO | Chief Executive Officer | - | - |
James Heath
DFI | Director of Finance/CFO | - | - |
Yao Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Capone
BRD | Director/Board Member | 61 | 21-03-17 |
Director/Board Member | - | 22-09-07 | |
Hyung-Tae Kim
BRD | Director/Board Member | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.185 | +2.78% | 30 151 |
24-04-26 | 0.18 | +12.50% | 344,355 |
24-04-24 | 0.16 | -5.88% | 245,709 |
24-04-23 | 0.17 | 0.00% | 478,630 |
24-04-22 | 0.17 | -8.11% | 265,958 |
Delayed Quote Australian S.E., April 29, 2024 at 12:54 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.78% | 52.57M | |
-16.58% | 8.25B | |
+39.20% | 3.58B | |
-39.11% | 2.46B | |
-8.41% | 2.46B | |
-8.45% | 2.38B | |
-19.01% | 1.55B | |
-40.66% | 1.21B | |
+7.56% | 1.11B | |
-15.03% | 1.03B |
- Stock Market
- Equities
- MAP Stock